News | July 21, 2021
Syngene Q1 FY22 revenue grows 41%
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
As per the agreement, Lonza will provide commercial-scale manufacture of monoclonal antibodies
The roller coaster ride during the pandemic has taken Indian pharmaceutical industry through a lot of bitter sweet experiences.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
AdCOVID is a COVID-19 vaccine candidate that is administered via nasal spray.
The partnership is a significant step in delivering advanced cancer therapies to patients.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
